178 related articles for article (PubMed ID: 20687221)
41. Delayed rectal and urinary symptomatology in patients treated for prostate cancer by radiotherapy with or without short term neo-adjuvant androgen deprivation.
Christie D; Denham J; Steigler A; Lamb D; Turner S; Mameghan H; Joseph D; Matthews J; Franklin I; Atkinson C; North J; Poulsen M; Spry NA; Tai KH; Wynne C; Duchesne G; Kovacev O; Francis L; Kramar A; D'Este C; Bill D
Radiother Oncol; 2005 Nov; 77(2):117-25. PubMed ID: 16271786
[TBL] [Abstract][Full Text] [Related]
42. Adverse effects of androgen deprivation therapy on persistent genitourinary complications after carbon ion radiotherapy for prostate cancer.
Ishikawa H; Tsuji H; Kamada T; Hirasawa N; Yanagi T; Mizoe JE; Akakura K; Suzuki H; Shimazaki J; Nakano T; Tsujii H
Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):78-84. PubMed ID: 18456419
[TBL] [Abstract][Full Text] [Related]
43. Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy.
Nanda A; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; D'Amico AV
Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1439-44. PubMed ID: 19540066
[TBL] [Abstract][Full Text] [Related]
44. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
[TBL] [Abstract][Full Text] [Related]
45. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect.
Ross RW; Xie W; Regan MM; Pomerantz M; Nakabayashi M; Daskivich TJ; Sartor O; Taplin ME; Kantoff PW; Oh WK
Cancer; 2008 Mar; 112(6):1247-53. PubMed ID: 18293426
[TBL] [Abstract][Full Text] [Related]
46. Maximum vs. mono androgen blockade and the risk of recurrence in men with localized prostate cancer undergoing brachytherapy.
Chen RC; Sadetsky N; Chen MH; Carroll PR; D'Amico AV
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):36-9. PubMed ID: 19233568
[TBL] [Abstract][Full Text] [Related]
47. Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE.
Abouassaly R; Paciorek A; Ryan CJ; Carroll PR; Klein EA
Cancer; 2009 Oct; 115(19):4470-6. PubMed ID: 19637339
[TBL] [Abstract][Full Text] [Related]
48. Predictors of fatigue after treatment for prostate cancer.
Maliski SL; Kwan L; Orecklin JR; Saigal CS; Litwin MS
Urology; 2005 Jan; 65(1):101-8. PubMed ID: 15667873
[TBL] [Abstract][Full Text] [Related]
49. Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance?
Perachino M; Cavalli V; Bravi F
BJU Int; 2010 Mar; 105(5):648-51. PubMed ID: 19747358
[TBL] [Abstract][Full Text] [Related]
50. Fracture risk in Danish men with prostate cancer: a nationwide register study.
Abrahamsen B; Nielsen MF; Eskildsen P; Andersen JT; Walter S; Brixen K
BJU Int; 2007 Oct; 100(4):749-54. PubMed ID: 17822455
[TBL] [Abstract][Full Text] [Related]
51. Chronic cancer-related fatigue in long-term survivors of testicular cancer.
Orre IJ; FossÄ SD; Murison R; Bremnes R; Dahl O; Klepp O; Loge JH; Wist E; Dahl AA
J Psychosom Res; 2008 Apr; 64(4):363-71. PubMed ID: 18374735
[TBL] [Abstract][Full Text] [Related]
52. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
Conde FA; Sarna L; Oka RK; Vredevoe DL; Rettig MB; Aronson WJ
Urology; 2004 Aug; 64(2):335-40. PubMed ID: 15302490
[TBL] [Abstract][Full Text] [Related]
53. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen Z; Lief JH; Adamovich E
Urology; 2005 Jan; 65(1):95-100. PubMed ID: 15667872
[TBL] [Abstract][Full Text] [Related]
54. Fatigue and other adverse effects in men treated by pelvic radiation and long-term androgen deprivation for locally advanced prostate cancer.
Lilleby W; Stensvold A; Dahl AA
Acta Oncol; 2016 Jul; 55(7):807-13. PubMed ID: 26959297
[TBL] [Abstract][Full Text] [Related]
55. Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer.
DiBlasio CJ; Malcolm JB; Derweesh IH; Womack JH; Kincade MC; Mancini JG; Ogles ML; Lamar KD; Patterson AL; Wake RW
BJU Int; 2008 Jul; 102(1):39-43. PubMed ID: 18294309
[TBL] [Abstract][Full Text] [Related]
56. Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy.
Palma D; Tyldesley S; Pickles T;
Cancer; 2008 May; 112(9):1941-8. PubMed ID: 18338814
[TBL] [Abstract][Full Text] [Related]
57. Predictors of physical activity and quality of life in New Zealand prostate cancer survivors undergoing androgen-deprivation therapy.
Keogh JW; Shepherd D; KrÀgeloh CU; Ryan C; Masters J; Shepherd G; MacLeod R
N Z Med J; 2010 Nov; 123(1325):20-9. PubMed ID: 21317957
[TBL] [Abstract][Full Text] [Related]
58. What is the optimal duration of androgen deprivation therapy in prostate cancer patients presenting with prostate-specific antigen levels > 20 ng/ml?
Berthelet E; Pickles T; Truong PT; Liu M; Pai HH; Kwan WB; Lim JT;
Can J Urol; 2007 Aug; 14(4):3621-7. PubMed ID: 17784982
[TBL] [Abstract][Full Text] [Related]
59. Body image perceptions in men with prostate cancer.
Harrington JM; Jones EG; Badger T
Oncol Nurs Forum; 2009 Mar; 36(2):167-72. PubMed ID: 19273405
[TBL] [Abstract][Full Text] [Related]
60. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy.
Moreau JP; Delavault P; Blumberg J
Clin Ther; 2006 Oct; 28(10):1485-508. PubMed ID: 17157109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]